亚虹医药APL-2401完成I期临床试验首例受试者入组

Core Viewpoint - Aihong Pharmaceutical (688176) has announced the completion of the first patient enrollment in a Phase I clinical trial for its self-developed drug APL-2401, targeting FGFR2/3-driven advanced solid tumors [1] Group 1 - APL-2401 is a highly selective small molecule inhibitor targeting fibroblast growth factor receptors 2 and 3 (FGFR2/3) [1] - The drug aims to provide a new treatment option for patients with advanced solid tumors, including urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [1]